SG10201802061TA - A selective inhibitor of phosphatidylinositol 3-kinase-gamma - Google Patents

A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Info

Publication number
SG10201802061TA
SG10201802061TA SG10201802061TA SG10201802061TA SG10201802061TA SG 10201802061T A SG10201802061T A SG 10201802061TA SG 10201802061T A SG10201802061T A SG 10201802061TA SG 10201802061T A SG10201802061T A SG 10201802061TA SG 10201802061T A SG10201802061T A SG 10201802061TA
Authority
SG
Singapore
Prior art keywords
phosphatidylinositol
kinase
gamma
selective inhibitor
inhibitor
Prior art date
Application number
SG10201802061TA
Other languages
English (en)
Inventor
Michael John Boyd
Alex Aronov
Hardwin O'dowd
Jeremy Green
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG10201802061TA publication Critical patent/SG10201802061TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201802061TA 2013-09-25 2014-09-25 A selective inhibitor of phosphatidylinositol 3-kinase-gamma SG10201802061TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361882473P 2013-09-25 2013-09-25

Publications (1)

Publication Number Publication Date
SG10201802061TA true SG10201802061TA (en) 2018-05-30

Family

ID=51795739

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201602265PA SG11201602265PA (en) 2013-09-25 2014-09-25 A selective inhibitor of phosphatidylinositol 3-kinase-gamma
SG10201802061TA SG10201802061TA (en) 2013-09-25 2014-09-25 A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201602265PA SG11201602265PA (en) 2013-09-25 2014-09-25 A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Country Status (18)

Country Link
US (1) US10301304B2 (pt)
EP (2) EP3412668B1 (pt)
JP (1) JP6340416B2 (pt)
KR (1) KR20160058950A (pt)
CN (1) CN105722838B (pt)
AU (1) AU2014324873B2 (pt)
BR (1) BR112016006388A2 (pt)
CA (1) CA2925601C (pt)
CL (1) CL2016000695A1 (pt)
ES (2) ES2687593T3 (pt)
HK (1) HK1223620A1 (pt)
IL (1) IL244742A0 (pt)
MX (1) MX2016003823A (pt)
RU (2) RU2675814C2 (pt)
SG (2) SG11201602265PA (pt)
UA (1) UA117032C2 (pt)
WO (1) WO2015048318A1 (pt)
ZA (1) ZA201702252B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2925944C (en) 2013-10-04 2023-01-10 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017004079A1 (en) 2015-06-29 2017-01-05 Biomed Valley Discoveries, Inc. Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3426652B1 (en) * 2016-03-10 2021-12-01 Astrazeneca AB Novel inhibitors of phosphatidylinositol 3-kinase gamma
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2022526854A (ja) 2019-04-10 2022-05-26 ナンジン・ジェンシアン・ファーマシューティカルズ・カンパニー・リミテッド ホスファチジルイノシトール３－キナーゼ阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US20120040950A1 (en) * 2009-12-22 2012-02-16 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase

Also Published As

Publication number Publication date
MX2016003823A (es) 2016-08-01
RU2016115726A3 (pt) 2018-06-20
BR112016006388A2 (pt) 2017-08-01
SG11201602265PA (en) 2016-04-28
US20160214980A1 (en) 2016-07-28
ZA201702252B (en) 2019-06-26
ES2785053T3 (es) 2020-10-05
EP3412668A3 (en) 2018-12-19
JP6340416B2 (ja) 2018-06-06
CA2925601A1 (en) 2015-04-02
KR20160058950A (ko) 2016-05-25
RU2018142605A (ru) 2019-02-04
EP3412668B1 (en) 2020-02-05
CN105722838A (zh) 2016-06-29
CN105722838B (zh) 2017-10-24
EP3049415A1 (en) 2016-08-03
HK1223620A1 (zh) 2017-08-04
EP3412668A2 (en) 2018-12-12
ES2687593T3 (es) 2018-10-26
AU2014324873B2 (en) 2018-11-08
CL2016000695A1 (es) 2017-06-09
RU2016115726A (ru) 2017-10-30
WO2015048318A1 (en) 2015-04-02
JP2016531861A (ja) 2016-10-13
IL244742A0 (en) 2016-04-21
EP3049415B1 (en) 2018-07-04
UA117032C2 (uk) 2018-06-11
RU2675814C2 (ru) 2018-12-25
AU2014324873A1 (en) 2016-04-21
US10301304B2 (en) 2019-05-28
CA2925601C (en) 2022-11-01

Similar Documents

Publication Publication Date Title
HK1248217A1 (zh) 選擇性cdk4/6抑制劑的固態形式
HK1220968A1 (zh) 磷脂酰肌醇 -激酶抑制劑
HK1214818A1 (zh) 選擇性的 抑制劑
EP2970340A4 (en) BETA-Lactamase INHIBITORS
HK1223620A1 (zh) 磷脂酰肌醇 -激酶-γ的選擇性抑制劑
EP2943204A4 (en) BETA-Lactamase INHIBITORS
EP2943901A4 (en) APPLICATION FOR MONITORING A PROPERTY OF A SURFACE
EP2948458A4 (en) BTK INHIBITORS
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
EP2948431A4 (en) BTK INHIBITORS
HK1216531A1 (zh) 新的抑制劑
GB201317609D0 (en) Inhibitor compounds
IL242803A0 (en) Dihydropyridinones as mgat2 inhibitors
GB201314578D0 (en) Bicyclic inhibitors
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
HK1215168A1 (zh) 戊糖素生成抑制劑
HK1221159A1 (zh) 轉移抑制劑
IL245386A0 (en) A crystalline beta-lactamase inhibitor
EP2959896A4 (en) INHIBITOR OF PHOSPHORYLATION OF PROTEIN T
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201307906D0 (en) Corrosion inhibitor